Their study illuminates the role of redox signaling in regulating the survival of DTP cancers and confirms the potential of targeting NPC1L1 by ezetimibe for treating MDR disease, thereby delaying cancer recurrence (Fig. 1b). The gene discussed is NPC1L1; the disease is cancer.